All In Biotech

Drug Trial Radar · NCT05919693

A 2-part Study Consisting of Multiple Ascending Dose (MAD) Safety Study, and a Dose-finding Masked Study to Assess the Safety and Efficacy of Intravitreal (IVT) Remigromig (EYE103) in Patients With Diabetic Macular Edema (DME) or Neovascular Age-related Macular Degeneration (NVAMD)

A 2-part Study Consisting of an Open-label Multiple Ascending Dose (MAD) Safety Study, and a Dose-finding Single-masked Comparative Safety and Preliminary Efficacy Study of Intravitreal (IVT) Remigromig in a Mixed Population of Participants With Diabetic Macular Edema (DME) or Neovascular Age-related Macular Degeneration (NVAMD)

Last checked: Nov 19, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

33

Actual

Start

Jun 12, 2023

Primary completion

Aug 26, 2024

Study completion Aug 26, 2024

Sponsor

Lead sponsor
EyeBiotech Ltd.Industry
Sponsor type
Industry
First posted
Jun 26, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Sequential
Masking
Triple (participant, care provider, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

EYE103-101 is a 2-part study assessing safety and preliminary efficacy of remigromig (EYE103) in patients with diabetic macular edema (DME) given as monotherapy or neovascular macular degeneration (NVAMD) given in combination with anti-VEGF. In the first part, termed the multiple ascending dose (MAD) portion of study, the safety of remigromig will be assessed at escalating doses. Approximately 12 participants will be entered in this part of the study. In the second part of the study, called the dose finding part two doses of remigromig will be selected and their effectiveness will be compared. Approximately 80 participants will be entered in this part of the study.

Conditions

  • Neovascular Age-related Macular Degeneration (NVAMD)
  • Diabetic Macular Edema (DME)

Interventions

  • RemigromigDrug

    Remigromig is a humanized antibody formulated for IVT administration

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants Who Experienced a Dose-limiting Toxicity (DLT)Time frame: Up to approximately 12 weeks
  2. Number of Participants Who Experienced an Adverse Event (AE)Time frame: Up to approximately 12 weeks
  3. Number of Participants Who Experienced a Serious Adverse Event (SAE)Time frame: Up to approximately 24 weeks
  4. Number of Participants Who Experienced Clinically Meaningful Changes in Laboratory AssessmentsTime frame: Baseline and Week 12
  5. Mean Change From Baseline in Best-Corrected Visual Acuity (BCVA) to Week 12 in the Study Eye - DME ParticipantsTime frame: Baseline and Week 12
  6. Mean Change From Baseline in BCVA to Week 12 in the Study Eye -NVAMD ParticipantsTime frame: Baseline and Week 12

Locations

32 sites in 4 countries. Site status is shown where the registry gives one.

  • Phoenix, AZ

    Phoenix, Arizona

  • Bakersfield, CA

    Bakersfield, California

  • Modesto, CA

    Modesto, California

  • Mountain View, CA

    Mountain View, California

  • Sacramento, CA

    Sacramento, California

  • Sacramento, CA

    Sacramento, California

  • Colorado Springs, Colorado

    Colorado Springs, Colorado

  • Lakewood, CO

    Lakewood, Colorado

  • Pompano Beach

    Pompano Beach, Florida

  • Lemont, NV

    Lemont, Illinois

  • Hagerstown, MD

    Hagerstown, Maryland

  • Reno, NV

    Reno, Nevada

  • West Columbia, SC

    West Columbia, South Carolina

  • Germantown, TN

    Germantown, Tennessee

  • Knoxville, TN

    Knoxville, Tennessee

  • Nashville, TN

    Nashville, Tennessee

  • Abilene, TX

    Abilene, Texas

  • Amarillo, TX

    Amarillo, Texas

  • Austin, TX

    Austin, Texas

  • Bellaire, TX

    Bellaire, Texas

  • Dallas, TX

    Dallas, Texas

  • Katy, TX

    Katy, Texas

  • McAllen, TX

    McAllen, Texas

  • Plano, TX

    Plano, Texas

  • Round Rock, TX

    Round Rock, Texas

  • San Antonio, TX

    San Antonio, Texas

  • The Woodlands, TX

    The Woodlands, Texas

  • Caba, Argentina

    Caba, Argentina

  • Ciudad Autonoma Buenos Aires

    Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina

  • Arecibo, PR

    Arecibo, PR, Puerto Rico

  • London, UK

    London, United Kingdom

  • London, England

    London, England, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.